Gain Therapeutics (GANX) Assets Average (2021 - 2026)

Gain Therapeutics has reported Assets Average for 6 years, with the latest figure at $17.1 million in Q2 2026.

• On a quarterly basis, Assets Average rose 59.2% year-over-year to $17.1 million in Q2 2026; TTM through Jun 2026 was $17.1 million, a 59.2% increase from a year earlier, with the FY2025 full-year figure at $17.5 million, up 13.7% from the prior year.
• Assets Average was $17.1 million for Q2 2026 at Gain Therapeutics, down from $20.8 million in the prior quarter.
• The five-year high for Assets Average was $38.3 million in Q1 2022, with the low at $10.4 million in Q3 2025.
• Average Assets Average over 5 years is $19.8 million, with a median of $16.9 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Assets Average slumped 46.26% in 2023, then surged 74.99% in 2026.
• Over 5 years, Assets Average stood at $26.2 million in 2022, then plunged by 37.61% to $16.4 million in 2023, then retreated by 19.01% to $13.2 million in 2024, then gained by 27.56% to $16.9 million in 2025, then climbed by 1.09% to $17.1 million in 2026.
• The last three Assets Average figures came in at $17.1 million (Q2 2026), $20.8 million (Q1 2026), and $16.9 million (Q4 2025), per Business Quant data.